BTLA Antikörper (Extracellular)
Kurzübersicht für BTLA Antikörper (Extracellular) (ABIN7877535)
Target
Alle BTLA Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- Extracellular
-
Verwendungszweck
- BTLA Antibody / CD272
-
Aufreinigung
- Protein G affinity chromatography
-
Immunogen
- Recombinant extracellular human CD272/BTLA protein was used as the immunogen for this BTLA antibody.
-
Isotyp
- IgG2b, kappa
-
-
-
-
Applikationshinweise
- Optimal dilution of the BTLA antibody should be determined by the researcher.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Store the BTLA antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
-
-
- BTLA (B and T Lymphocyte Associated (BTLA))
-
Andere Bezeichnung
- BTLA
-
Hintergrund
- B and T lymphocyte attenuator (BTLA) is an immunoglobulin domain-containing glycoprotein whose expression is induced during T-cell activation. BTLA is similar to CTLA-4 and PD-1, all of which are coinhibitory receptors belonging to the CD28 family. However, unlike CTLA-4 and PD-1, BTLA does not interact with B7-Ig family counter receptors. Rather, the herpesvirus entry mediator (HVEM), a TNF receptor, acts as a molecular switch that modulates T-cell activation by propagating inhibitory signals through BTLA. The BTLAHVEM interaction is conserved between Mouse and human, suggesting that this system is an important pathway regulating lymphocyte activation.
-
UniProt
- Q7Z6A9
-
Pathways
- Cancer Immune Checkpoints
Target
-